Lantern Pharma (LTRN) Competitors

MediWound (NASDAQ:MDWD) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Is MDWD or LTRN more profitable?

Lantern Pharma has a net margin of 0.00% compared to MediWound's net margin of -142.18%. MediWound's return on equity of -96.71% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-142.18%	-96.71%	-39.73%
Lantern Pharma	N/A	-99.89%	-81.58%

Which has more volatility and risk, MDWD or LTRN?

MediWound has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Do analysts rate MDWD or LTRN?

MediWound currently has a consensus target price of $32.25, indicating a potential upside of 93.11%. Lantern Pharma has a consensus target price of $25.00, indicating a potential upside of 512.75%. Given Lantern Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Lantern Pharma is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Lantern Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, MDWD or LTRN?

Lantern Pharma has lower revenue, but higher earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$20.22M	8.93	-$30.22M	-$2.64	-6.33
Lantern Pharma	N/A	N/A	-$20.78M	-$1.78	-2.29

Does the media favor MDWD or LTRN?

In the previous week, MediWound had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for MediWound and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat MediWound's score of 0.94 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MediWound	Positive
Lantern Pharma	Very Positive

Do insiders and institutionals believe in MDWD or LTRN?

46.8% of MediWound shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MediWound and Lantern Pharma tied by winning 7 of the 14 factors compared between the two stocks.